Acute palmoplantar eczema (dyshidrotic eczema)
- David R Adams, MD, PharmD
David R Adams, MD, PharmD
- Associate Professor of Dermatology
- Penn State Hershey Med Center
- James G Marks, Jr, MD
James G Marks, Jr, MD
- Professor and Chair, Department of Dermatology
- Penn State Milton S. Hershey Medical Center
Acute palmoplantar eczema (more popularly known as dyshidrotic eczema or pompholyx) is an intensely pruritic, vesicular eruption affecting the palms, soles, or both [1,2]. It is characterized by deep-seated lesions ranging from small vesicles to large tense bullae clinically and by spongiotic vesicles histologically. Recurrence is common and patients typically experience frequent episodes for months or years.
This topic will discuss the pathogenesis, clinical presentation, diagnosis, and management of dyshidrotic eczema. Other forms of eczema involving the hands, including irritant and allergic contact dermatitis and atopic dermatitis, are discussed separately. (See "Irritant contact dermatitis in adults" and "Clinical features and diagnosis of allergic contact dermatitis" and "Management of allergic contact dermatitis" and "Pathogenesis, clinical manifestations, and diagnosis of atopic dermatitis (eczema)" and "Treatment of atopic dermatitis (eczema)".)
The terminology for acute palmoplantar eczema is confusing. The term "dyshidrosis" was coined in 1873 to describe a blistering disease of the palms and soles that was believed to be a disorder of the sweat glands . It is now accepted that the sweat glands are not involved in the pathogenesis [4,5]. However, the term "dyshidrotic eczema" continues to be used.
Other terms for acute palmoplantar eczema include pompholyx, dyshidrosis, vesicular palmoplantar eczema, acute and recurrent vesicular hand dermatitis, cheiropompholyx (affecting the hands), or podopompholyx (affecting the feet). These terms do not represent a specific diagnosis, but rather a morphologic pattern of hand/foot eczema that can occur with irritant contact, allergic contact, or endogenous eczema.
The prevalence of dyshidrotic eczema, including mild and severe forms of dyshidrotic eczema, in the general population is unknown. In occupational or clinical settings, dyshidrotic eczema accounts for 5 to 20 percent of all cases of hand dermatitis [6,7]. It occurs most commonly in young adults and equally among males and females. Risk factors for dyshidrotic eczema include history of atopic dermatitis and exposure to contact allergens or irritants [8-10]. A rare autosomal dominant form of dyshidrotic eczema has been described .
- Veien NK. Acute and recurrent vesicular hand dermatitis. Dermatol Clin 2009; 27:337.
- Wollina U. Pompholyx: a review of clinical features, differential diagnosis, and management. Am J Clin Dermatol 2010; 11:305.
- Lofgren SM, Warshaw EM. Dyshidrosis: epidemiology, clinical characteristics, and therapy. Dermatitis 2006; 17:165.
- SHELLEY WB. Dysidrosis (pompholyx). AMA Arch Derm Syphilol 1953; 68:314.
- Kutzner H, Wurzel RM, Wolff HH. Are acrosyringia involved in the pathogenesis of "dyshidrosis"? Am J Dermatopathol 1986; 8:109.
- Meding B, Swanbeck G. Epidemiology of different types of hand eczema in an industrial city. Acta Derm Venereol 1989; 69:227.
- Agner T, Aalto-Korte K, Andersen KE, et al. Classification of hand eczema. J Eur Acad Dermatol Venereol 2015; 29:2417.
- de Boer EM, Bruynzeel DP, van Ketel WG. Dyshidrotic eczema as an occupational dermatitis in metal workers. Contact Dermatitis 1988; 19:184.
- Jain VK, Aggarwal K, Passi S, Gupta S. Role of contact allergens in pompholyx. J Dermatol 2004; 31:188.
- Lodi A, Betti R, Chiarelli G, et al. Epidemiological, clinical and allergological observations on pompholyx. Contact Dermatitis 1992; 26:17.
- Chen JJ, Liang YH, Zhou FS, et al. The gene for a rare autosomal dominant form of pompholyx maps to chromosome 18q22.1-18q22.3. J Invest Dermatol 2006; 126:300.
- Pitché P, Boukari M, Tchangai-Walla K. [Factors associated with palmoplantar or plantar pompholyx: a case-control study]. Ann Dermatol Venereol 2006; 133:139.
- Guillet MH, Wierzbicka E, Guillet S, et al. A 3-year causative study of pompholyx in 120 patients. Arch Dermatol 2007; 143:1504.
- Veien NK, Hattel T, Justesen O, Nørholm A. Oral challenge with metal salts. (I). Vesicular patch-test-negative hand eczema. Contact Dermatitis 1983; 9:402.
- Lehucher-Michel MP, Koeppel MC, Lanteaume A, Sayag J. Dyshidrotic eczema and occupation: a descriptive study. Contact Dermatitis 2000; 43:200.
- Uyttendaele H, Obadiah J, Grossman M. Dyshidrotic-like spongiotic dermatitis after intravenous immunoglobulin therapy. J Drugs Dermatol 2003; 2:337.
- Iannaccone S, Sferrazza B, Quattrini A, et al. Pompholyx (vesicular eczema) after i.v. immunoglobulin therapy for neurologic disease. Neurology 1999; 53:1154.
- Gerstenblith MR, Antony AK, Junkins-Hopkins JM, Abuav R. Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy. J Am Acad Dermatol 2012; 66:312.
- Shiraishi T, Yamamoto T. Severe dyshidrotic eczema after intravenous immunoglobulin therapy for Kawasaki syndrome. Pediatr Dermatol 2013; 30:e30.
- Douwes KE, Karrer S, Abels C, et al. Does smoking influence the efficacy of bath-PUVA therapy in chronic palmoplantar eczema? Photodermatol Photoimmunol Photomed 2000; 16:25.
- Man I, Ibbotson SH, Ferguson J. Photoinduced pompholyx: a report of 5 cases. J Am Acad Dermatol 2004; 50:55.
- Hald M, Agner T, Blands J, et al. Clinical severity and prognosis of hand eczema. Br J Dermatol 2009; 160:1229.
- Vocks E, Plötz SG, Ring J. The Dyshidrotic Eczema Area and Severity Index - A score developed for the assessment of dyshidrotic eczema. Dermatology 1999; 198:265.
- Warshaw EM. Therapeutic options for chronic hand dermatitis. Dermatol Ther 2004; 17:240.
- Ashcroft DM, Dimmock P, Garside R, et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ 2005; 330:516.
- Belsito DV, Fowler JF Jr, Marks JG Jr, et al. Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis 2004; 73:31.
- Thelmo MC, Lang W, Brooke E, et al. An open-label pilot study to evaluate the safety and efficacy of topically applied tacrolimus ointment for the treatment of hand and/or foot eczema. J Dermatolog Treat 2003; 14:136.
- Schnopp C, Remling R, Möhrenschlager M, et al. Topical tacrolimus (FK506) and mometasone furoate in treatment of dyshidrotic palmar eczema: a randomized, observer-blinded trial. J Am Acad Dermatol 2002; 46:73.
- Pariser D. Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption. Am J Ther 2009; 16:264.
- Tzaneva S, Kittler H, Thallinger C, et al. Oral vs. bath PUVA using 8-methoxypsoralen for chronic palmoplantar eczema. Photodermatol Photoimmunol Photomed 2009; 25:101.
- Polderman MC, Govaert JC, le Cessie S, Pavel S. A double-blind placebo-controlled trial of UVA-1 in the treatment of dyshidrotic eczema. Clin Exp Dermatol 2003; 28:584.
- Sezer E, Etikan I. Local narrowband UVB phototherapy vs. local PUVA in the treatment of chronic hand eczema. Photodermatol Photoimmunol Photomed 2007; 23:10.
- Petering H, Breuer C, Herbst R, et al. Comparison of localized high-dose UVA1 irradiation versus topical cream psoralen-UVA for treatment of chronic vesicular dyshidrotic eczema. J Am Acad Dermatol 2004; 50:68.
- Egan CA, Rallis TM, Meadows KP, Krueger GG. Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx. J Am Acad Dermatol 1999; 40:612.
- Granlund H, Erkko P, Eriksson E, Reitamo S. Comparison of cyclosporine and topical betamethasone-17,21-dipropionate in the treatment of severe chronic hand eczema. Acta Derm Venereol 1996; 76:371.
- ETIOLOGY AND PATHOGENESIS
- CLINICAL PRESENTATION
- Clinical diagnosis
- Patch testing
- DIFFERENTIAL DIAGNOSIS
- CLINICAL COURSE
- Assessment of severity
- General measures
- Mild to moderate disease
- - Topical corticosteroids
- - Topical calcineurin inhibitors
- Severe disease
- - Systemic corticosteroids
- - Topical corticosteroids
- Treatment response
- Refractory disease
- - Evaluation
- - Treatment
- SUMMARY AND RECOMMENDATIONS